<DOC>
	<DOCNO>NCT00606086</DOCNO>
	<brief_summary>The GI-5005 therapeutic vaccine combination standard care standard care alone inject skin HCV subject . Patients monitor safety , immune response therapeutic benefit relate injection include EVR , ETR , SVR .</brief_summary>
	<brief_title>Safety Efficacy Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard Care Therapy Versus Standard Care Alone Patients With Genotype 1 Chronic Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Chronic hepatitis C infection genotype 1 base serum positivity HCV RNA positive test serum antiHCV antibody least 6 month ; One follow response criterion base response prior combination therapy pegylated nonpegylated interferon plus ribavirin : NonResponders Poor responder subset nonresponders achieve &gt; 1 log10 &lt; 2 log10 reduction HCV RNA minimum 12 week prior interferon base therapy . Partial responder subset nonresponders achieve least 2 log10 reduction HCV RNA 12 week , achieve end treatment response ( ETR define HCV RNA negativity PCR assay end minimum 6 month therapy ) . Naive Patients treatment naïve refuse IFN therapy reason contraindication . Signed , write , informed consent patient legal representative studyspecific procedure perform ; Liver biopsy within 3 year screen visit , document extent liver disease consistent chronic hepatitis C evidence inflammation and/or fibrosis . Liver biopsy within 1 year subject consent paired biopsy test . Eight unstained liver biopsy slide require baseline sample posttreatment sample use central blinded evaluation pair biopsy testing ; Age ≥ 18 year ; Negative scratch test ( immediate hypersensitivity , IgE mediate ) S. cerevisiae . History decompensated liver disease , include restrict , portal hypertension manifest known history gastroesophageal varix , variceal bleeding , ascites encephalopathy , histopathologic clinical evidence cirrhosis , hepatocellular carcinoma , renal impairment consistent hepatorenal syndrome ; History significant nonHCV chronic liver disease , i.e . alcoholic hepatitis , autoimmune hepatitis ; Null response prior IFN plus ribavirin therapy , define patient receive least 12 week interferonbased treatment &lt; 1 log10 reduction viral load ; Subjects treat 1 complete hepatitis C regimen ( subject history 1 complete prior regimen second incomplete prior regimen may eligible upon discussion approval medical monitor ) ; Subjects require dose reduction &gt; 25 % plan exposure IFN &gt; 50 % plan ribavirin exposure previous interferon/ribavirin treatment ; Subjects require growth factor previous interferon/ribavirin treatment ; Subjects receive small molecule inhibitor therapy combine interferon base regimen . ( subject receive small molecule inhibitor monotherapy include ) ; Treatment HCV infection within 28 day screen ; Chronic hepatitis B infection positive hepatitis B surface antigen ( HBsAg ) screening ; Body weight &gt; 275 pound ; Known history HIV infection positive HIV antibody test screening ; History Crohn 's disease ulcerative colitis ; Concurrent therapy herbal supplement take specifically treatment HCV ( i.e . milk thistle ) . Washout HCV related herbal 28 day prior Day 1 . Consult sponsor exclude potential subject ; Alcohol and/or IV drug abuse within past year ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Hepatitis , HCV , Liver disease , HepC</keyword>
</DOC>